Oatmeal cancer claim questioned

Apr 04, 2008

Danish health experts are questioning a claim that oatmeal is a carcinogen.

A book by government health adviser Ane Bodil Sogaard says oatmeal contains acrylamide, which has been shown to cause cancer in laboratory rats, the Copenhagen Post said Thursday.

Christian Molgaard of the Danish Fitness and Nutrition Council said Sogaard's claim overstates the true risk.

"Of course we want to try and minimize our intake of unnecessary health-damaging substances in our foods, but we believe that oatmeal is a very good choice for breakfast because of its high-fiber content and low levels of sugar," Molgaard told consumer news site epn.dk.

A representative for the Danish Cancer Society said the levels of acrylamide levels in oatmeal are very low.

"I think it would be problematic if we scared Danes away from eating it," said Anne Tjonneland. "And not just because its acrylamide levels are very low -- far lower than most breakfast products -- but also due to its direct nutritional value."

Copyright 2008 by United Press International

Explore further: Sperm bank sued after donor details emerge 7 years later

Related Stories

Mexico boosts protection of near-extinct porpoise

49 minutes ago

Mexico is greatly expanding a protected area of the Gulf of California and boosting navy patrols in an effort to save the vaquita marina, a small porpoise facing imminent extinction.

Court monitor: Apple antitrust cooperation has 'declined'

49 minutes ago

Apple Inc.'s cooperation with efforts to improve its compliance with antitrust laws after a federal judge concluded it colluded with electronic book publishers to raise prices five years ago took on an "adversarial tone" ...

SEC questions LA Unified on use of bonds for iPad project

51 minutes ago

The Securities and Exchange Commission recently questioned Los Angeles Unified School District officials as part of informal inquiry into whether they properly used bond funds for a beleaguered $1.3 billion project to provide ...

Recommended for you

Cardinal Health paying $26.8 million in FTC settlement

15 hours ago

Cardinal Health will pay $26.8 million as part of a settlement with the Federal Trade Commission over charges it monopolized the sale in 25 markets of diagnostic drugs known as low-energy radiopharmaceuticals.

Selecting the right tool for the job

Apr 14, 2015

Randomized clinical trials of new drugs have long been considered the "gold standard" in determining safety and efficacy before drugs, biologics, vaccines or devices are introduced to the general public. However, in the case ...

User comments : 0

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.